OncoMethylome is developing molecular diagnostic tests to assist the physician in making more informed diagnoses and treatment decisions. Specifically, OncoMethylome is developing two types of tests:
  • Molecular Cancer Diagnostics are designed to accurately identify people who are likely to have early stage cancer and therefore need further examination
  • Personalized Treatment Solutions are designed to predict a patient's response to specific drug therapy (pharmacogenomic test), or the likelihood of cancer recurrence or metastatic potential, for more individualized cancer treatment

The Schering-Plough® name and S-P Logo® are federally registered trademarks of Schering Corporation, used with permission.